A Review on pharmacology and recent analytical methods for estimation of Desvenlafaxine hydrochloride

Prashant Kumar Sahu*, Jitendra Yadav, Dolly Dewangan, Kamraj, Krity Gupta, Manish Kumar Sahu, Parimal Verma, Shweta Sinha, Aakanksha Sinha, S. J. Daharwal

University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur (C.G).

*Corresponding Author E-mail:

ABSTRACT:

Desvenlafaxine, the primary active compound found in venlafaxine, is used to treat major depressive disorder in adults as a serotonin-norepinephrine reuptake inhibitor. Its pharmacological effects come from selectively inhibiting SERT and NET, with a stronger preference for serotonin transporters. Studies have shown that desvenlafaxine has a moderate but reliable effectiveness as an antidepressant, although not as powerful as venlafaxine. Recent findings suggest that it could also be beneficial for managing pain, supported by changes seen in VAS-PI scores. Various methods, such as UV spectrophotometry, HPTLC, HPLC, UHPLC, and LC-MS/MS, have been developed to measure desvenlafaxine in raw material, formulations, and biological samples. These methods differ in how sensitive and specific they are, as well as their practical use, but there has not been a comprehensive review of their performance. This article summarizes the pharmacological actions, clinical effects, and all known analytical techniques for desvenlafaxine to serve as a comprehensive resource for research and quality control purposes.

KEYWORDS: Desvenlafaxine, Analytical Methods, UV-Spectroscopy, HPLC, HPTLC.

INTRODUCTION:

Desvenlafaxine is an antidepressant belonging to the SNRI class, used to treat the major depressive disorder. It is a synthetic compound containing phenethylamine bicyclic structure and it is the main active metabolite of venlafaxine - its chemical name is O-desmethylvenlafaxine.¹

The US Food Drug Administration (FDA) approved it in February 2008 for the treatment of adults who have major depressive disorder (MDD).² Even though the FDA hasn't officially approved it for teenagers yet, studies called TORDIA have shown that medicines like venlafaxine, which help improve mood by working on chemicals in the brain called serotonin and norepinephrine, can be helpful in treating serious depression in teenagers who haven't gotten better with other treatments.³

Physicochemical Properties:

Desvenlafaxine, the main active form of venlafaxine, is considered an SNRI and is given in clinical settings as desvenlafaxine succinate monohydrate. Its chemical structure (C₁₆H₂₅NO₂) allows it to selectively inhibit the reuptake of serotonin and norepinephrine, with much greater affinity for serotonergic transporters. The substance does not significantly interact with muscarinic, cholinergic, H₁-histaminergic, and α₁-adrenergic receptors and does not inhibit monoamine oxidase. In terms of how the body processes it, the substance behaves in a linear manner, with slow absorption resulting in a peak concentration after 7-8 hours, an oral bioavailability of about 80%, and a half-life of around 11 hours. Elimination primarily occurs through the kidneys (~45%) and through UGT-mediated conjugation, with minimal involvement of CYP3A4 and no reliance on CYP2D6.^2,4

Mechanism of Action:

Desvenlafaxine, a medication commonly used to treat major depressive disorder, functions primarily through the dual inhibition of serotonin (5-HT) and norepinephrine (NE) reuptake transporters, known as SERT and NET respectively. By blocking these transporters, desvenlafaxine increases the extracellular concentrations of both neurotransmitters, leading to enhanced activation of their respective receptors. This heightened receptor activity improves neurotransmission within key brain regions involved in mood regulation, such as the prefrontal cortex and limbic system. The balanced inhibition of both serotonin and norepinephrine pathways helps alleviate depressive symptoms by improving mood, energy levels, and overall emotional stability. Additionally, this mechanism can contribute to better cognitive function and reduced anxiety, making desvenlafaxine an effective option for many patients suffering from depression. Its targeted approach aims to restore neurotransmitter balance and promote mental well-being.^1,2,5

Clinical Efficacy:

Two recent 8-week clinical studies comparing desvenlafaxine to venlafaxine in patients with major depression yielded mixed outcomes. In one study, desvenlafaxine showed no significant advantage over placebo, suggesting limited efficacy in that trial. Conversely, the other study favoured venlafaxine, demonstrating superior results in reducing depressive symptoms. When data from both studies were combined, overall analysis revealed that both medications led to improvements in depression scores compared to baseline. However, venlafaxine consistently outperformed desvenlafaxine, with higher response and remission rates observed among patients taking venlafaxine. These findings highlight the varying efficacy profiles of these two antidepressants and underscore the importance of individualized treatment approaches in managing major depression.⁶

Pharmacology:

Pharmacokinetic:

Desvenlafaxine exhibits linear pharmacokinetics across a dose range of 100 to 900 mg, indicating that its plasma concentration increases proportionally with the dose administered. It has an approximate half-life of 11 hours, allowing it to reach steady-state levels in about four days of consistent dosing. This predictable pharmacokinetic profile supports its use in managing depression and related conditions effectively.¹

The compound exhibits extensive tissue distribution and has low plasma protein binding, approximately 30%, indicating widespread dissemination throughout the body.² Desvenlafaxine is primarily metabolized via glucuronidation, with mediation occurring through various UGT isoforms (UGT1A1, 1A3, 2B4, 2B15, 2B17). Oxidative metabolism (N-demethylation) involves only minimal contribution from CYP3A4, while the absence of CYP2D6 involvement prevents interindividual variability arising from CYP2D6 polymorphisms (a phenomenon observed in venlafaxine). Around 45–46% of the administered quantity is eliminated unadulterated in urine, alongside roughly 19% appearing as the O-glucuronide metabolite. Conversion to N, O-didesmethylvenlafaxine via oxidative metabolism accounts for under 5%.^6,7

Pharmacodynamic:

Desvenlafaxine is a synthetic compound derived from phenethylamine that is the primary active metabolite of venlafaxine. It is in the form of a succinate salt monohydrate and functions as a serotonin-norepinephrine reuptake inhibitor (SNRI). Desvenlafaxine selectively blocks the human serotonin transporter (hSERT) and norepinephrine transporter (hNET), inhibiting the reuptake of serotonin and norepinephrine.(1,2,5,7–11) Desvenlafaxine has a significantly higher affinity for the serotonin transporter (hSERT) compared to the norepinephrine transporter (hNET), with binding constants of 40.2 ± 1.6 nM and 558.4 ± 121.6 nM, respectively. The half-maximal inhibitory concentration values further support this selectivity, with values of 47.3 ± 19.4 nM for serotonin reuptake and 531.3 ± 113 nM for norepinephrine reuptake.²

Radioligand-binding assays and PET imaging studies show that both the R-enantiomer and racemic form of desvenlafaxine bind to serotonin transporters in a dose-dependent manner. The racemate exhibits greater SERT occupancy, with 50% occupancy achieved at approximately 14.4 mg compared to 24.8 mg for the R-enantiomer. Desvenlafaxine has minimal affinity for various other receptors, including muscarinic, cholinergic, H₁-histaminergic, α₁-adrenergic, dopaminergic, GABAergic, and opioid receptors, and does not inhibit monoamine oxidase (MAO). Therefore, its antidepressant effects primarily result from inhibiting monoamine transporters rather than directly affecting receptors.^1,6

Desvenlafaxine was found to raise levels of norepinephrine in the hypothalamus during in vivo microdialysis studies. Additionally, when a 5-HT₁A receptor blocker was present, serotonin levels also increased, indicating that desvenlafaxine has a dual effect on both norepinephrine and serotonin pathways. This dual action is believed to be responsible for its effectiveness in treating major depressive disorder (MDD) and potentially in alleviating symptoms of menopausal vasomotor dysfunction through modulation of hypothalamic SERT and NET.²

New Indication: Pain:

Desvenlafaxine is currently under investigation for its potential in treating pain. The effectiveness of DVS in treating Major Depressive Disorder was initially confirmed through large multicenter trials that included a pain assessment using the Visual Analog Scale – Pain Intensity (VAS-PI). The VAS-PI is a 100 mm straight line where the left end signifies no pain and the right end represents the most severe pain.^5,12

Analytical Method:

Numerous analytical techniques have been developed and optimized for the estimation of desvenlafaxine in bulk drug and dosage forms. These analytical techniques include UV-visible spectrophotometry, high-performance liquid chromatography (HPLC), high-performance thin-layer chromatography (HPTLC), spectrofluorimetry, and liquid chromatography–mass spectrometry (LC–MS). All these techniques offer distinct advantages in terms of selectivity, precision, and detection and various aspects of quantitative or qualitative manner.

Table 1: Development on UV-visible spectroscopy

Method	Matrix	Reagent/Solvent	λ (nm)	Linearity	LOD	LOQ	Ref.
UV	Bulk	Ethanol	236.40	100μg/ml	1.88μg/ml	6.26μg/ml	(13)
UV	Bulk	Water	224	5-40μg/ml	_	_	(14)
UV	Bulk	Distilled Water	230	10-50μg/ml	_	_	(15)
UV	Tablet	Distilled Water	230	10-50ug/ml	_	_	(15)

Table 2: High performance thin layer chromatography

Method	Matrix	Mobile Phase	Chamber saturation (min)	Detection (nm)	Retention Factor (R_f)	Linearity Range (ng spot^-1)	LOD (ng spot^-1)	LOQ (ng spot^-1)	Ref.
HPTLC	Bulk	Ethyl acetate: toluene: methanol: ammonia (7:2:0.5:0.5, v/v/v/v)	30 min	228 nm	-	100-1000	10	100	(4)
HPTLC	Tablet	Methanol: toluene: glacial acetic acid (7:3:0.3, v/v/v)	30 min	226 nm	0.43 ± 0.02	200–1200	53	167	(16)
HPTLC	Tablet	Ethyl acetate: n-hexane: triethyl amine (5.0: 4.5: 0.5 v/v/v)	10 min	226 nm	-	100-500	6.947	21.05	(17)

Table 3: Liquid chromatography

Method	Matrix	Mobile Phase	Column	*λ (nm)*	Flowrate (mL min⁻¹⁾	Retention Time (min)	Linearity	LOD	LOQ	Ref.
LC-UV LC-MS	Bulk Tablet	0.2% in 0.05M Ammonium Acetate: Methanol (40:60 v/v)	Symmetry Shield column C18 (5 μm, 250 mm×4.6 mm)	228	1.00	4.87	10-80 μgmL^-1	5 μg/mL	10 μg/mL	(18)
LC	Tablet	0.05 M potassium dihydrogen phosphate: methanol (60:40 v/v)	Hypersil C-18, 250 mm×4.6 mm, 5 μm	226	1.00	7.4	0.1-20 μgmL^-1	-	-	(19)
LC- ESI-MS/M	Bulk	5 mM ammonium acetate buffer: methanol (20:80, v/v)	Thermo-BDS hypersil C8 column (50 × 4.6 mm, 3 μm)	-	0.80	1.25	1.001–400.352 μg/mL	-	(LLOQ) 1.001 ng/mL	(20)
RP-HPLC	Bulk	Acetonitrile: 5 mM 𝐾𝐻₂𝑃𝑂₄ solution (50:50 v/v)	Discovery® C-18 (250 × 4.6 mm, 5 μm)	229	0.7	3.5	5-100 μgmL^-1	1.147	3.476	(21)
RP-HPLC	Tablet	Acetonitrile : 0.02 M KH₂PO₄ buffer (65:35, v/v) with 0.1% TFA	Hypersil BDS C18 (250mm×4.6mm, 5μm)	230	1.00	4.011	10–150.0 μgmL^-1	4.740	14.365	(22)
UHPLC	Bulk	1%(TFA): Methanol (30:70)	Eclipse XDB-C8 column (150 x 4.6 mm, 5μm)	210	1.5	2.333	80-120 μg/ml	0.8	2.4	(23)
HPLC	Bulk	acetonitrile and phosphate buffer.	Capcell Pak C-18 column	226	1	-	1-1000 μg/mL	2.8	9.4	(24)
RP-HPLC	Tablet	“A” phosphate Buffer pH6.5& Methanol in the ratio (80:20)	Hypersil Gold C18 (150 × 4.6 mm, 3μm)	225	1.3	2.17	25-150 μg/ml	0.083	0.276	(25)
RP-HPLC	Tablet	“B” phosphate Buffer& methanol in the ratio (10:90)	Hypersil Gold C18 (150 × 4.6 mm, 3μm)	225	1.3	2.17	25-150 μg/ml	0.083	0.276	(25)

CONCLUSION:

Desvenlafaxine is a primary active metabolite of venlafaxine, is a synthetic serotonin-norepinephrine reuptake inhibitor (SNRI) that acts primarily by selectively blocking the human serotonin transporter (hSERT) and norepinephrine transporter (hNET). It reaches steady-state levels in approximately four days and has linear pharmacokinetics with an approximate half-life of 11 hours. Metabolism is regulated by glucuronidation by several UGT isoforms; notably, CYP2D6 is not involved, which prevents the unpredictable behavior seen with venlafaxine. In addition to being used to treat Major Depressive Disorder (MDD), desvenlafaxine is currently being studied for its potential to relieve pain.

Modern pharmaceutical analysis relies on a wide range of analytical tools, ranging from basic UV–Vis measurements to high-resolution chromatographic systems such as HPTLC, HPLC, and UHPLC to maintain reliable quality control. While sophisticated instrumentation, especially mass spectrometers, enhance sensitivity, specialized stationary phases and tightly calibrated mobile-phase compositions improve selectivity. These well-established processes, which are validated by observed linear response ranges, ensure the identity and quantitative accuracy of chemicals in raw materials and finished dosage forms. However, based on current efficiency and sustainability standards, shorter run times, lower solvent usage, and lower detection limits remain feasible aims for methodology improvements, indicating a strong need for further research and development.

REFERENCE:

1. Norman TR, Olver JS. Desvenlafaxine in the treatment of major depression: an updated overview. Expert Opin Pharmacother. 2021 June 13;22(9):1087–97.

2. Perry R, Cassagnol M. Desvenlafaxine: A new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009 Jan;31:1374–404.

3. Naseeruddin R, Rosani A, Marwaha R. Desvenlafaxine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Nov 2]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK534829/

4. Pawar SM, Dhaneshwar SR. Application Of Stability Indicating High Performance Thin Layer Chromatographic Method For Quantitation Of Desvenlafaxine In Pharmaceutical Dosage Form. J Liq Chromatogr Relat Technol. 2012 Feb 15;35(4):499–510.

5. Lieberman DZ. Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy. Core Evid. 2009 June;67.

6. Shelton RC. Serotonin Norepinephrine Reuptake Inhibitors: Similarities and Differences. Prim Psychiatry. 2009;16(5).

7. Kornstein SG, McIntyre RS, Thase ME, Boucher M. Desvenlafaxine for the treatment of major depressive disorder. Expert Opin Pharmacother. 2014 July 3;15(10):1449–63.

8. Andrade C. Desvenlafaxine. Indian J Psychiatry. 2009;51(4):320–3.

9. Nichols AI, Tourian KA, Tse SY, Paul J. Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin–norepinephrine reuptake inhibitor. Expert Opin Drug Metab Toxicol. 2010 Dec;6(12):1565–74.

10. Munoli RN, Praharaj SK, Bhandary RP, Selvaraj AG. Desvenlafaxine-induced worsening of hypertension. J Neuropsychiatry Clin Neurosci. 2013;25(2):E29-30.

11. DeMaio W, Kane C, Nichols A, Jordan R. Metabolism Studies of Desvenlafaxine. J Bioequivalence Bioavailab. 2011 Jan 1;03.

12. Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale: Pain. 1983 May;16(1):87–101.

13. Kalyani L, Harpriya C, Rehana M. Analytical method development and validation for Desvenlafaxine Succinate by UV-Visible Spectroscopy Method. Int J Pharm. 2022;

14. Patil MG, Banerjee SK, Bonde CG, Chhabra gs. Uv spectrophotometric method development for the determination of desvenlafaxine succinate in tablet formulation.

15. Manjusha N. Dole*, Amit S. Minase, Sangeeta Chowdhary and Sanjay D. Sawant. Development and validation of analytical methods for estimation of desvenlafaxine succinate in bulk and solid dosage forms by UV spectroscopy. Sch Res Libr. 2013;

16. Shah D, Nakrani R, Baldania S, Chhalotiya U, Bhatt K. Development and validation of HPTLC method for the estimation of desvenlafaxine in tablet formulation. J Planar Chromatogr – Mod TLC. 2012 Apr;25(2):174–7.

17. Tawale H, Tajne M. Validated High Performance Thin Layer Chromatography Method For Determination Of Desvenlafaxine Succinate In Tablet.

18. Pawar SM, Khatal LD, Gabhe SY, Dhaneshwar SR. LC–UV and LC–MS evaluation of stress degradation behavior of desvenlafaxine. J Pharm Anal. 2012 Aug;2(4):264–71.

19. Shah D, Nakrani R, Baldania S, Chhalotiya U, Bhatt K. Stability indicating liquid chromatographic method for the estimation of desvenlafaxine in pharmaceutical dosage form. Chem Ind Chem Eng Q. 2011;17(3):341–8.

20. Kancharla PK, Kondru VGR, Dannana GS. Novel LC‐ ESI‐MS/MS method for desvenlafaxine estimation human plasma: application to pharmacokinetic study. Biomed Chromatogr. 2016 Feb;30(2):249–55.

21. Moussa BA, El-Bagary RI, Al-Eryani YA. Development and Validation of a Stability-Indicating HPLC Method for the Analysis of Desvenlafaxine Succinate in the Presence of its Acidic Induced Degradation Product in Bulk and Pharmaceutical Preparation. 2011;

22. Rao H, Ahmad S, Madni A, Ahmad I, Shahzad MN. Single-step extraction for simultaneous quantification of desvenlafaxine and alprazolam in human spiked plasma by RP-HPLC. Sailor G, editor. PLOS ONE. 2020 Sept 17;15(9):e0238954.

23. Akter H, Alam MM, Rabbi MR, Shamsur Rouf AS. Stability-Indicating UHPLC Method for the Determination of Desvenlafaxine: Application to Degradation Kinetics. Dhaka Univ J Pharm Sci. 2021 Dec 29;20(2):167–76.

24. Dziurkowska E, Wesolowski M. Simultaneous quantitation of venlafaxine and its main metabolite, O-desmethylvenlafaxine, in human saliva by HPLC. J Sep Sci. 2013;36(11):1726–33.

25. Vankadari RMG, P P, G.V R, Y G. Development and validation of stability indicating rp-hplc method for the determination of desvenlafaxine in extended release tablets. Indo Am J Pharm Res. 2013 Jan 1;3:7325–35.

Received on 30.09.2025 Revised on 17.10.2025

Accepted on 10.11.2025 Published on 28.11.2025

Available online from December 31, 2025

Research J. Engineering and Tech. 2025; 16(4):162-166.

DOI: 10.52711/2321-581X.2025.00016

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.